Viridian Therapeutics Inc

  • TickerVRDN
  • ISINUS92790C1045
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
 PRESS RELEASE
VRDN Viridian Therap... (Health Care)

Viridian Therapeutics Appoints Kristian Humer as Chief Financial Offic...

Viridian Therapeutics Appoints Kristian Humer as Chief Financial Officer and Chief Business Officer BOULDER, Colo., July 26, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced the appointment of Kristian Humer as its new Chief Financial Officer and Chief Business Officer. “Kristian brings extensive global finance experience as our new CFO and CBO. His appointment builds upon the tremendously talented team of executives w...

 PRESS RELEASE
VRDN Viridian Therap... (Health Care)

Viridian Therapeutics Appoints Jennifer Moses, CPA to the Board of Dir...

Viridian Therapeutics Appoints Jennifer Moses, CPA to the Board of Directors and as Chair of the Audit Committee BOULDER, Colo., July 15, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced the appointment of Jennifer Moses, CPA to the Company’s Board of Directors and as Chair of the Audit Committee. “We are excited to welcome Jennifer to our Board of Directors and as Chair of the Audit Committee. She provides strong fina...

Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
 PRESS RELEASE
VRDN Viridian Therap... (Health Care)

Viridian Therapeutics Reports First Quarter 2021 Financial Results and...

Viridian Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates VRDN-001 and VRDN-002 programs for Thyroid Eye Disease (TED) progressing; on track for IND filings in fourth quarter of 2021Reported $117 million in cash, cash equivalents and short-term investments as of March 31, 2021; cash runway into 2024 BOULDER, Colo., May 06, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by current therapies, today announced financia...

Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
 PRESS RELEASE
VRDN Viridian Therap... (Health Care)

Viridian Therapeutics Appoints Kristian Humer as Chief Financial Offic...

Viridian Therapeutics Appoints Kristian Humer as Chief Financial Officer and Chief Business Officer BOULDER, Colo., July 26, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced the appointment of Kristian Humer as its new Chief Financial Officer and Chief Business Officer. “Kristian brings extensive global finance experience as our new CFO and CBO. His appointment builds upon the tremendously talented team of executives w...

 PRESS RELEASE
VRDN Viridian Therap... (Health Care)

Viridian Therapeutics Appoints Jennifer Moses, CPA to the Board of Dir...

Viridian Therapeutics Appoints Jennifer Moses, CPA to the Board of Directors and as Chair of the Audit Committee BOULDER, Colo., July 15, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced the appointment of Jennifer Moses, CPA to the Company’s Board of Directors and as Chair of the Audit Committee. “We are excited to welcome Jennifer to our Board of Directors and as Chair of the Audit Committee. She provides strong fina...

Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
 PRESS RELEASE
VRDN Viridian Therap... (Health Care)

Viridian Therapeutics Reports First Quarter 2021 Financial Results and...

Viridian Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates VRDN-001 and VRDN-002 programs for Thyroid Eye Disease (TED) progressing; on track for IND filings in fourth quarter of 2021Reported $117 million in cash, cash equivalents and short-term investments as of March 31, 2021; cash runway into 2024 BOULDER, Colo., May 06, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by current therapies, today announced financia...

Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
 PRESS RELEASE
VRDN Viridian Therap... (Health Care)

Viridian Therapeutics Appoints Kristian Humer as Chief Financial Offic...

Viridian Therapeutics Appoints Kristian Humer as Chief Financial Officer and Chief Business Officer BOULDER, Colo., July 26, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced the appointment of Kristian Humer as its new Chief Financial Officer and Chief Business Officer. “Kristian brings extensive global finance experience as our new CFO and CBO. His appointment builds upon the tremendously talented team of executives w...

 PRESS RELEASE
VRDN Viridian Therap... (Health Care)

Viridian Therapeutics Appoints Jennifer Moses, CPA to the Board of Dir...

Viridian Therapeutics Appoints Jennifer Moses, CPA to the Board of Directors and as Chair of the Audit Committee BOULDER, Colo., July 15, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced the appointment of Jennifer Moses, CPA to the Company’s Board of Directors and as Chair of the Audit Committee. “We are excited to welcome Jennifer to our Board of Directors and as Chair of the Audit Committee. She provides strong fina...

Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
 PRESS RELEASE
VRDN Viridian Therap... (Health Care)

Viridian Therapeutics Reports First Quarter 2021 Financial Results and...

Viridian Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates VRDN-001 and VRDN-002 programs for Thyroid Eye Disease (TED) progressing; on track for IND filings in fourth quarter of 2021Reported $117 million in cash, cash equivalents and short-term investments as of March 31, 2021; cash runway into 2024 BOULDER, Colo., May 06, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by current therapies, today announced financia...

Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields

ResearchPool Subscriptions

Get the most out of your insights

Get in touch